Logo
x

Search category

Subscribe Now

All Posts by Date

Insights+ Key Biosimilars Events of September 2021

Insights+ Key Biosimilars Events of September 2021

Pfizer Signs an Option and License Agreement with Voyager to Develop and Commercialize Gene Therapies for Neurologic and Cardiovascular Diseases

Pfizer Signs an Option and License Agreement with Voyager to Develop and Commercialize Gene Therapies for Neurologic and Cardiovas...

Sanofi Reports Interim Results of Fluzone High-Dose Quadrivalent Vaccine + COVID-19 mRNA Booster Dose in First Descriptive Study for COVID-19

Sanofi Reports Interim Results of Fluzone High-Dose Quadrivalent Vaccine + COVID-19 mRNA Booster Dose in First Descriptive Study f...

PharmaTher Initiates P-II KET-LID Study of Ketamine for Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease

PharmaTher Initiates P-II KET-LID Study of Ketamine for Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease

Denali Presented Results of DNL343 and SAR443820 in P-I Clinical Studies for the Treatment of Amyotrophic Lateral Sclerosis at NEALS 2021

Denali Presented Results of DNL343 and SAR443820 in P-I Clinical Studies for the Treatment of Amyotrophic Lateral Sclerosis at NEA...

BMS Deucravacitinib Fails to Meet its Primary and Secondary Endpoints in P-II LATTICE-UC Study for the Treatment of Moderate to Severe Ulcerative Colitis

BMS Deucravacitinib Fails to Meet its Primary and Secondary Endpoints in P-II LATTICE-UC Study for the Treatment of Moderate to Se...

Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2022 PharmaShots - All Rights Reserved.